References
Key articles
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):e1-33.Full text Abstract
World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Sep 2022 [internet publication].Full text
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-95.Full text Abstract
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Mycobacterium tuberculosis infection and disease. May 2024 [internet publication].Full text
Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-142.Full text Abstract
World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. Module 1: prevention. 2020 [internet publication].Full text
World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Dec 2022 [internet publication]Full text Abstract
British HIV Association. BHIVA guidelines for the management of tuberculosis in adults living with HIV 2018 (2023 interim update). 2023 [internet publication].Full text
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. May 2022 [internet publication].Full text
Reference articles
1. Polesky A, Grove W, Bhatia G. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. Medicine (Baltimore). 2005 Nov;84(6):350-62. Abstract
2. Baumann MH, Nolan R, Petrini M, et al. Pleural tuberculosis in the United States: incidence and drug resistance. Chest. 2007 Apr;131(4):1125-32. Abstract
3. Ong A, Creasman J, Hopewell PC, et al. A molecular epidemiological assessment of extrapulmonary tuberculosis in San Francisco. Clin Infect Dis. 2004 Jan 1;38(1):25-31. Abstract
4. World Health Organization. Tuberculosis. 2023 [internet publication].Full text
5. World Health Organization. Global tuberculosis report 2023. Nov 2023 [internet publication].Full text
6. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2022. Nov 2023 [internet publication].Full text
7. Gonzalez OY, Adams G, Teeter LD, et al. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis. 2003 Dec;7(12):1178-85. Abstract
8. Yang Z, Kong Y, Wilson F, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis. 2004 Jan 15;38(2):199-205. Abstract
9. European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2024 - 2022 data. Mar 2024 [internet publication].Full text
10. UK Health Security Agency. Tuberculosis in England, 2022 report (data up to end of 2021). Aug 2023 [internet publication].Full text
11. Dye C. Global epidemiology of tuberculosis. Lancet. 2006 Mar 18;367(9514):938-40.Full text Abstract
12. GBD 2019 Tuberculosis Collaborators. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022 Feb;22(2):222-41.Full text Abstract
13. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004 May 13;350(20):2060-7. Abstract
14. Chow KM, Chow VC, Hung LC, et al. Tuberculous peritonitis-associated mortality is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples. Clin Infect Dis. 2002 Aug 15;35(4):409-13. Abstract
15. Iseman MD. A clinician's guide to tuberculosis. Baltimore: Lippincott, Williams & Wilkins, 1999.
16. Colditz GA, Brewer TF, Berkley CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. JAMA. 1994 Mar 2;271(9):698-702. Abstract
17. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012 Feb 3;148(3):434-46.Full text Abstract
18. Thuong NTT, Heemskerk D, Tram TTB, et al. Leukotriene A4 hydrolase genotype and HIV infection influence intracerebral inflammation and survival from tuberculous meningitis. J Infect Dis. 2017 Apr 1;215(7):1020-8.Full text Abstract
19. Musellim B, Erturan S, Sonmez Duman E, et al. Comparison of extra-pulmonary and pulmonary tuberculosis cases: factors influencing the site of reactivation. Int J Tuberc Lung Dis. 2005 Nov;9(11):1220-3. Abstract
20. Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000 Dec;162(6):2033-8.Full text Abstract
21. American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000 Apr;161(4 pt 2):S221-47.Full text Abstract
22. Zuber PL, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA. 1997 Jul 23-30;278(4):304-7. Abstract
23. Gonzalez OY, Teeter LD, Thanh BT, et al. Extrathoracic tuberculosis lymphadenitis in adult HIV seronegative patients: a population-based analysis in Houston, Texas, USA. Int J Tuber Lung Dis. 2003 Oct;7(10):987-93. Abstract
24. Thwaites G, Chau TT, Mai NT, et al. Tuberculous meningitis. J Neurol Neurosurg Psych. 2000 Mar;68(3):289-99. Abstract
25. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med. 1997 Jan 15;126(2):123-32. Abstract
26. Daley CL, Small PM, Schechter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency syndrome. N Engl J Med. 1992 Jan 23;326(4):231-5. Abstract
27. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2;320(9):545-50. Abstract
28. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006 Nov;2(11):602-10. Abstract
29. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006 Feb 15;55(1):19-26. Abstract
30. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004 May 1;38(9):1261-5. Abstract
31. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006 Jun 1;42(11):1592-5. Abstract
32. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555-64. Abstract
33. Rieder HL, Snider DE Jr, Cauthen GM, et al. Extrapulmonary tuberculosis in the United States. Am Rev Resp Dis. 1990 Feb;141(2):347-51. Abstract
34. Cantwell MF, McKenna MT, McCray E, et al. Tuberculosis and race/ethnicity in the United States, impact of socioeconomic status. Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1016-20.Full text Abstract
35. Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018 Jul 12;379(2):138-49.Full text Abstract
36. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - tuberculosis. May 2023 [internet publication].Full text
37. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - perspectives: testing travelers for mycobacterium tuberculosis infection. May 2023 [internet publication].Full text
38. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):e1-33.Full text Abstract
39. World Health Organization. WHO consolidated guidelines on tuberculosis module 3: diagnosis - rapid diagnostics for tuberculosis detection. Mar 2024 [internet publication].Full text
40. Parimon T, Spitters CE, Muangman N, et al. Unexpected pulmonary involvement in extrapulmonary tuberculosis patients. Chest. 2008 Sep;134(3):589-94.Full text Abstract
41. World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Sep 2022 [internet publication].Full text
42. Kohli M, Schiller I, Dendukuri N, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021 Jan 15;1:CD012768.Full text Abstract
43. Kay AW, González Fernández L, Takwoingi Y, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020 Aug 27;8:CD013359.Full text Abstract
44. Bjerrum S, Schiller I, Dendukuri N, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev. 2019 Oct 21;10:CD011420.Full text Abstract
45. Nathavitharana RR, Lederer P, Chaplin M, et al. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. Cochrane Database Syst Rev. 2021 Aug 20;8:CD014641.Full text Abstract
46. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-95.Full text Abstract
47. Hooper C, Lee YC, Maskell N; BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults. Thorax. 2010 Aug;65 Suppl 2:ii4-17.Full text Abstract
48. Kim HJ, Lee Hj, Kwon SY, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest. 2006 May;129(5):1253-8. Abstract
49. Siebert AF, Haynes J Jr, Middleton R, et al. Tuberculous pleural effusion: twenty-year experience. Chest. 1991 Apr;99(4):883-6. Abstract
50. Mariconda M,Cozzolino A, Attingenti P, et al. Osteoarticular tuberculosis in a developed country. J Infect. 2007 Apr;54(4):375-80. Abstract
51. Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009 Sep;59(3):167-87. Abstract
52. Thwaites GE, Chau TT, Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol. 2004 Jan;42(1):378-9.Full text Abstract
53. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4. Abstract
54. Arendt K, Demaerschalk BM, Wingerchuk DM, et al. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20. Abstract
55. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204. Abstract
56. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.Full text Abstract
57. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.Full text Abstract
58. Arevalo-Rodriguez I, Ciapponi A, Roqué i Figuls M, et al. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2016 Mar 7;(3):CD009199.Full text Abstract
59. Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculosis peritonitis: a meta-analysis. J Clin Gastroenterol. 2006 Sep;40(8):705-10. Abstract
60. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48.Full text Abstract
61. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.Full text Abstract
62. Bernardi M, Caraceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.Full text Abstract
63. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.Full text Abstract
64. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol. 2000 Jan;32(1):142-53. Abstract
65. Van Hoving DJ, Griesel R, Meintjes G, et al. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. Cochrane Database Syst Rev. 2019 Sep 30;9:CD012777.Full text Abstract
66. Elder N. Extrapulmonary tuberculosis. Arch Fam Med. 1992 Sep;1(1):91-8. Abstract
67. Kim JH, Langston AA, Gallis HA. Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome. Rev Infect Dis. 1990 Jul-Aug;12(4):583-90. Abstract
68. Crump JA, Reller LB. Two decades of disseminated tuberculosis at a university medical center: the expanding role of mycobacterial blood culture. Clin Infect Dis. 2003 Oct 15;37(8):1037-43. Abstract
69. Maartens G, Willcox, Benatar SR, et al. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities and outcome in 109 treated adults. Am J Med. 1990 Sep;89(3):291-6. Abstract
70. Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2015 Apr;78(2):47-55.Full text Abstract
71. World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: tests for TB infection. Sep 2022 [internet publication].Full text
72. Geldmacher H, Taube C, Kroeger C, et al. Assessment of lymph node tuberculosis in northern Germany: a clinical review. Chest. 2002 Apr;121(4):1177-82. Abstract
73. Shriner KA, Mathisen GE, Goetz MB. Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. Clin Infect Dis. 1992 Oct;15(4):601-5. Abstract
74. Gopi A, Madhaven SM, Sharma SK, et al. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest. 2007 Mar;131(3):880-9. Abstract
75. Weir MR, Thorton GF. Extrapulmonary tuberculosis: experience of a community hospital and review of the literature. Am J Med. 1985 Oct;79(4):467-78. Abstract
76. Baydur A. The spectrum of extrapulmonary tuberculosis. West J Med. 1977 Apr;126(4):253-62. Abstract
77. Powell DA. Tuberculous lymphadenitis and parotitis. In: Schlossberg D, ed. Tuberculosis and nontuberculous mycobacterial infections, 5th ed. Berkshire, UK: 2006.
78. Jha BC, Dass A, Nagarkar NM, et al. Cervical tuberculous lymphadenopathy: changing clinical pattern and concepts in management. Postgrad Med J. 2001 Mar;77(905):185-7. Abstract
79. Nataraj G, Kurup S, Pandit A, et al. Correlation of fine needle aspiration cytology, smear and culture in tuberculous lymphadenitis: a prospective study. J Postgrad Med. 2002 Apr-Jun;48(2):113-6. Abstract
80. Singh KK, Muralidhar M, Kumar A, et al. Comparison of in house polymerase chain reaction with conventional techniques for the detection of Mycobacterium tuberculosis DNA in granulomatous lymphadenopathy. J Clin Pathol. 2000 May;53(5):355-61. Abstract
81. Field S, Lewis S. Intestinal and peritoneal tuberculosis. In: Rom WN, Garay S, eds. Tuberculosis, 2nd ed. Philadelphia: Lippincott, Williams and Wilkins; 2003.
82. Kirsch CM, Kroe DM, Azzi RL, et al. The optimal number of pleural biopsy specimens for a diagnosis of tuberculous pleurisy. Chest. 1997 Sep;112(3):702-6. Abstract
83. Willcox PA, Potgieter PD, Bateman ED, et al. Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope. Thorax. 1986 Sep;41(9):681-4. Abstract
84. Lai KK, Stottmeier KD, Sherman IH, et al. Mycobacterial cervical lymphadenopathy: relationship of etiologic agents to age. JAMA. 1984 Mar 9;251(10):1286-8. Abstract
85. Xu HB, Jiang RH, Li L, et al. Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: a meta-analysis. Int J Tuberc Lung Dis. 2010 Nov;14(11):1382-7. Abstract
86. US Preventive Services Task Force. Latent tuberculosis infection in adults: screening. May 2023 [internet publication].Full text
87. World Health Organization. WHO consolidated guidelines on tuberculosis: module 6: tuberculosis and comorbidities. Apr 2024 [internet publication].Full text
88. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Mycobacterium tuberculosis infection and disease. May 2024 [internet publication].Full text
89. Nolt D, Starke JR. Tuberculosis infection in children and adolescents: testing and treatment. Pediatrics. 2021 Dec 1;148(6):e2021054663.Full text Abstract
90. National Tuberculosis Controllers Association. Testing and treatment of latent tuberculosis infection in the United States: clinical recommendations. 2021 [internet publication].Full text
91. American College of Radiology. ACR appropriateness criteria: hemoptysis. 2019 [internet publication].Full text
92. Field SK, Escalante P, Fisher DA, et al; CHEST Expert Cough Panel. Cough due to TB and other chronic infections: CHEST Guideline and Expert Panel Report. Chest. 2018 Feb;153(2):467-97.Full text Abstract
93. World Health Organization. WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease. Mar 2021 [internet publication].Full text
94. WHO: Tuberculosis
95. Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11.Full text Abstract
96. Panel on Opportunistic Infections in Children With and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. Sep 2024 [internet publication].Full text
97. Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723-6.Full text Abstract
98. Belknap R, Holland D, Feng PJ, et al; TB Trials Consortium iAdhere Study Team. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017 Nov 21;167(10):689-97. Abstract
99. Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015 Mar;169(3):247-55. Abstract
100. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8;365(23):2155-66.Full text Abstract
101. Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018 Aug 2;379(5):440-53.Full text Abstract
102. Diallo T, Adjobimey M, Ruslami R, et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018 Aug 2;379(5):454-63.Full text Abstract
103. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-142.Full text Abstract
104. World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. Module 1: prevention. 2020 [internet publication].Full text
105. Committee on Infectious Diseases, American Academy of Pediatrics. Tuberculosis. In: Kimberlin DW, Banerjee R, Barnett ED, ed(s). Red book: 2024-2027 report of the Committee on Infectious Diseases. 33rd ed. Itasca, IL: American Academy of Pediatrics; 2024.
106. Mangan JM, Woodruff RS, Winston CA, et al. Recommendations for use of video directly observed therapy during tuberculosis treatment - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):313-6.Full text Abstract
107. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: tuberculosis care and support. Jul 2022 [internet publication].Full text
108. World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Dec 2022 [internet publication]Full text Abstract
109. World Health Organization. WHO announces updated definitions of extensively drug-resistant tuberculosis. Jan 2021 [internet publication].Full text
110. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016 Apr 28;(4):CD002244.Full text Abstract
111. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004 Oct 21;351(17):1741-51. Abstract
112. Donovan J, Bang ND, Imran D, et al. Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults. N Engl J Med. 2023 Oct 12;389(15):1357-67.Full text Abstract
113. Wiysonge CS, Ntsekhe M, Thabane L, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD000526.Full text Abstract
114. British HIV Association. BHIVA guidelines for the management of tuberculosis in adults living with HIV 2018 (2023 interim update). 2023 [internet publication].Full text
115. Rusu A, Munteanu AC, Arbănași EM, et al. Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile? Pharmaceutics. 2023 Mar 1;15(3):804.Full text Abstract
116. World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. May 2022 [internet publication].Full text
117. Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001-11.Full text Abstract
118. Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-18.Full text Abstract
119. Carr W, Kurbatova E, Starks A, et al. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 25;71(8):285-9.Full text Abstract
120. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. May 2022 [internet publication].Full text
121. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020 Mar 5;382(10):893-902.Full text Abstract
122. Centers for Disease Control and Prevention. Provisional CDC guidance for the use of pretomanid as part of a regimen [bedaquiline, pretomanid, and linezolid (BPaL)] to treat drug-resistant tuberculosis disease. Feb 2024 [internet publication].Full text
123. World Gastroenterology Organisation. WGO practice guideline - digestive tract tuberculosis. Mar 2021 [internet publication].Full text
124. World Health Organization. Tuberculosis and air travel: guidelines for prevention and control. 2008 [internet publication].Full text
125. Anyama N, Bracebridge S, Black C, et al. What happens to people diagnosed with tuberculosis? A population-based cohort. Epidemiol Infect. 2007 Oct;135(7):1069-76. Abstract
126. Fielder JF, Chaulk CP, Dalvi M, et al. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002 Dec;6(12):1114-7. Abstract
127. Straetemans M, Glaziou P, Bierrenbach AL, et al. Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS One. 2011 Jun 27;6(6):e20755.Full text Abstract
128. Long R, O'Connor R, Palayew M, et al. Disseminated tuberculosis with and without a miliary pattern on chest radiograph: a clinical-pathologic-radiologic correlation. Int J Tuberc Lung Dis. 1997 Feb;1(1):52-8. Abstract
129. Hawkey CR, Yap T, Pereira J, et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis. 1997 Feb;1(1):52-8. Abstract
130. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N EnglJ Med. 2010 Jul 15;363(3):257-65.Full text Abstract
131. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb 25;362(8):697-706.Full text Abstract
132. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998 Jul;158(1):157-61.Full text Abstract
133. Cheng V, Ho P, Lee R, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):803-9. Abstract
134. Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006 Dec;53(6):357-63. Abstract
135. Heemskerk AD, Bang ND, Mai NT, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016 Jan 14;374(2):124-34.Full text Abstract
136. Mishra R, Patel HK, Singasani R, et al. Tuberculosis septic shock, an elusive pathophysiology and hurdles in management: a case report and review of literature. World J Crit Care Med. 2019 Sep 11;8(5):72-81.Full text Abstract
137. British Thoracic Society. BTS Pleural disease guideline 2010. August 2010 [internet publication]. [This guideline has been archived by the British Thoracic Society. The BTS website states that guidelines that are more than 5 years old are marked as archived because their recommendations have not been checked to confirm continued validity at the date of archival. A BMJ Best Practice expert adviser has confirmed that these guidelines still reflect current practice in the UK.]Full text
138. National Patient Safety Agency. Rapid response report: risks of chest drain insertion. May 2008. http://www.nrls.npsa.nhs.uk/ (last accessed 26 October 2017).Full text
139. Akram AR, Hartung TK. Intercostal chest drains: a wake-up call from the National Patient Safety Agency rapid response report. J R Coll Physicians Edinb. 2009;39:117-120.Full text
140. American College of Surgeons Committee on Trauma. Advanced trauma life support (ATLS) student course manual. 8th ed. Chicago, IL: American College of Surgeons; 2008.
141. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. Abstract
142. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 1999 Oct 14;341(16):1174-9. Abstract
Use of this content is subject to our disclaimer